Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Eli Lilly poised for 30-50% growth in 12 months with strong value and growth nexus. Discover why risks lead to elite returns.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

In its first-quarter 2025 investor letter, Macquarie Large Cap Growth Fund highlighted stocks such as Eli Lilly and Company ...

Bimagrumab showed promising fat loss results in a mid-stage trial, but analysts raised concerns about safety and say more ...

Eli Lilly & Co. is bouncing back after a turbulent period, riding out volatility and posting a strong revenue increase in Q1 ...

Microsoft Corporation (NASDAQ:MSFT) is one of the 10 best AI stocks to buy according to billionaire David Tepper. Bloomberg reported on June 18 that the conglomerate is planning a new round of layoffs ...